Securities code: Boji Medical Technology Co.Ltd(300404) securities abbreviation: Boji Medical Technology Co.Ltd(300404) Announcement No.: 2022015 Boji Medical Technology Co.Ltd(300404)
Announcement on signing the supervision agreement on raised funds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Basic information of raised funds
With the approval of China Securities Regulatory Commission on the approval of Guangzhou Boji Medical Technology Co.Ltd(300404) Biotechnology Co., Ltd. to issue shares to specific objects for registration (zjxk [2020] No. 3230), Boji Medical Technology Co.Ltd(300404) (hereinafter referred to as “the company” or ” Boji Medical Technology Co.Ltd(300404) “) issued 33450584 A shares to specific objects at an issue price of 10.26 yuan / share, The total amount of funds raised is 34320299184 yuan, after deducting 678627395 yuan of various issuance expenses (excluding value-added tax), the net amount of funds actually raised by the company is 33641671789 yuan. All the above raised funds have been received on June 18, 2021, verified by zhongxinghua Certified Public Accountants (special general partnership) and issued the capital verification report (zhongxinghuayan Zi (2021) No. 410005).
2、 Signing of supervision agreement on raised funds and account opening
The company held the 17th meeting of the 4th board of directors and the 15th meeting of the 4th board of supervisors on January 26, 2022, deliberated and adopted the proposal on changing the implementation subject and place of some raised capital investment projects and increasing capital to wholly-owned subsidiaries, Agree to change the implementation subject of “innovative drug R & D service platform construction project” from Shenzhen Brightgene Bio-Medical Technology Co.Ltd(688166) Technology Co., Ltd. (hereinafter referred to as “Shenzhen Borui”), a wholly-owned subsidiary of the company, to Shenzhen Borui, Boji Medical Technology Co.Ltd(300404) ; It is agreed to change the implementation subject of the “clinical research service network expansion and capacity improvement project” from Boji Medical Technology Co.Ltd(300404) to Boji Medical Technology Co.Ltd(300404) , a wholly-owned subsidiary of Shanghai farmars Pharmaceutical Biotechnology Co., Ltd. (hereinafter referred to as “farmars”). For details, see the announcement on changing the implementation subject and place of some raised capital investment projects and increasing capital to wholly-owned subsidiaries (Announcement No.: 2022010) issued by the company on cninfo.com on January 27, 2022.
In order to regulate the management and use of raised funds and protect the rights and interests of small and medium-sized investors, in accordance with relevant laws and According to the regulations and normative documents and the company’s management system for raised funds, the company and farmars have newly established a special account for raised funds. Recently, the company signed the tripartite supervision agreement on raised funds with Citic Securities Company Limited(600030) (hereinafter referred to as ” Citic Securities Company Limited(600030) ” or “sponsor”) and Industrial And Commercial Bank Of China Limited(601398) Guangzhou Yuexiu sub branch; The company, farmars and the recommendation agency signed the four party supervision agreement on raised funds with Shanghai Pudong Development Bank Co.Ltd(600000) Guangzhou Dongshan sub branch to implement special account management on the deposit and use of raised funds. The details are as follows:
No. account holder name of Bank of deposit bank account No. purpose of raised funds
1 Boji Medical Technology Co.Ltd(300404) China Industrial And Commercial Bank Of China Limited(601398) Co., Ltd. 360208572925782578 platform construction project of Guangzhou Yuexiu sub branch of innovative drug R & D Service Company
Shanghai Pudong Development Bank Co., Ltd. clinical research service network 2 weights Co., Ltd. Guangzhou Dongshan sub branch 8204078801 Shenzhen Kaifa Technology Co.Ltd(000021) 16 network expansion and capacity improvement project
3、 Main contents of the raised funds supervision agreement
1. As of February 15, 2022, the balance of the special account 360208572925782578 is RMB 0 million; As of February 13, 2022, the balance of the special account 82040078801 Shenzhen Kaifa Technology Co.Ltd(000021) 16 was RMB 10000. The special account for the raised funds is only used for the storage and use of the raised funds of the raised investment projects specified in the agreement, and shall not be used for other purposes.
2. The company, farmars and the deposit bank shall jointly abide by the bill law of the people’s Republic of China, the measures for payment and settlement, the measures for the administration of RMB bank settlement accounts and other laws, regulations and rules.
3. Citic Securities Company Limited(600030) as the company’s recommendation agency, it shall appoint a recommendation representative or other staff to supervise the use of the raised funds of the company and farmars in accordance with relevant regulations Citic Securities Company Limited(600030) shall perform its supervision duties in accordance with the guidelines for self discipline supervision of listed companies No. 2 – standardized operation of companies listed on GEM and the raised funds management system formulated by the company, and have the right to exercise its supervision power by means of on-site investigation and written inquiry. The company, farmars and the Bank of deposit shall cooperate with the investigation and inquiry of Citic Securities Company Limited(600030) Citic Securities Company Limited(600030) at least every six months, the company and farmars shall check the storage of the raised funds in the special account at the same time.
4. Xue Wanbao and song Yongxin, the sponsor representatives designated by Citic Securities Company Limited(600030) authorized by the company and farmars, can inquire and copy the information of the company and farmars’ special account at the Bank of deposit at any time; The deposit bank shall timely, accurately and completely provide it with the required information about the special account. When checking the legal identity of the sponsor and the sponsor’s representative of the account Citic Securities Company Limited(600030) other staff members designated by Citic Securities Company Limited(600030) shall issue their legal identity certificate and letter of introduction when inquiring about the company and farmars special account from the deposit bank. 5. The deposit bank shall issue a statement of account to the company and farmars on a monthly basis (before the 10th of each month), with a copy to Citic Securities Company Limited(600030) . The deposit bank shall ensure that the statements are true, accurate and complete.
6. If the company and farmars withdraw more than 50 million yuan from the special account or 20% of the net raised funds in one time or within 12 months, whichever is lower, the company, farmars and the deposit bank shall timely notify Citic Securities Company Limited(600030) , and provide the expenditure list of the special account.
7. Citic Securities Company Limited(600030) has the right to change the designated sponsor representative according to relevant regulations Citic Securities Company Limited(600030) if the sponsor representative is replaced, the Bank of deposit shall be notified in writing of relevant supporting documents, and the contact information of the replaced sponsor representative shall be notified in writing to the company, farmars and the Bank of deposit in accordance with the requirements of this agreement. The replacement of the sponsor representative shall not affect the effectiveness of this agreement.
8. If the deposit bank fails to timely issue a statement to Citic Securities Company Limited(600030) or notify Citic Securities Company Limited(600030) of the large withdrawal of the special account for three consecutive times, and fails to cooperate with Citic Securities Company Limited(600030) investigation of the special account, the company and farmars have the right to unilaterally terminate this Agreement and cancel the special account for raised funds.
9. This Agreement shall come into force from the date when the legal representatives (principals) or their authorized representatives of each party sign and affix the official seal or special seal for contract of their respective units, and shall become invalid after all the funds in the special account are spent and the Citic Securities Company Limited(600030) supervision period ends.
4、 Documents for future reference
1. Tripartite supervision agreement on raised funds
2. Four party supervision agreement on raised funds
It is hereby announced.
Boji Medical Technology Co.Ltd(300404) board of directors March 3, 2022
